PPIDT00021
Drug Information
| Name | Peginterferon alfa-2b |
|---|---|
| Sequence | CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE |
| DrugBank_ID | DB00022 |
| Type | biotech |
| Indication | Peginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. It is also indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection, including complete lymphadenectomy.[L45334] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Subcutaneous |
100 mcg/0.5ml
|
| Injection, powder, for solution | Subcutaneous |
120 mcg/0.5ml
|
| Injection, powder, for solution | Subcutaneous |
150 mcg/0.5ml
|
| Injection, powder, for solution | Subcutaneous |
50 mcg/0.5ml
|
| Injection, powder, for solution | Subcutaneous |
80 mcg/0.5ml
|
| Capsule; powder, for solution | Oral; Subcutaneous |
|
| Injection, powder, for solution; kit | Subcutaneous |
120 ug/0.5mL
|
| Injection, powder, for solution; kit | Subcutaneous |
150 ug/0.5mL
|
| Injection, powder, for solution; kit | Subcutaneous |
50 ug/0.5mL
|
| Injection, powder, for solution; kit | Subcutaneous |
80 ug/0.5mL
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
120 ug/0.5mL
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
150 ug/0.5mL
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
50 ug/0.5mL
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
80 ug/0.5mL
|
| Kit | Subcutaneous |
120 ug/0.5mL
|
| Kit | Subcutaneous |
150 ug/0.5mL
|
| Kit | Subcutaneous |
50 ug/0.5mL
|
| Kit | Subcutaneous |
80 ug/0.5mL
|
| Injection, solution | — |
100 mcg
|
| Injection, solution | — |
120 mcg
|
| Injection, solution | — |
150 mcg
|
| Injection, solution | — |
50 mcg
|
| Injection, solution | — |
80 mcg
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
5000000 mcg
|
| Kit | Subcutaneous |
120 ug/0.1mL
|
| Kit | Subcutaneous |
40 ug/0.1mL
|
| Kit | Subcutaneous |
60 ug/0.1mL
|
| Powder, for solution | Subcutaneous |
118.4 mcg / vial
|
| Powder, for solution | Subcutaneous |
177.6 mcg / vial
|
| Powder, for solution | Subcutaneous |
222 mcg / vial
|
| Powder, for solution | Subcutaneous |
74 mcg / vial
|
| Injection, powder, for solution | Subcutaneous |
100 MCG
|
| Injection, powder, for solution | Subcutaneous |
120 MCG
|
| Injection, powder, for solution | Subcutaneous |
150 MCG
|
| Injection, powder, for solution | Subcutaneous |
50 MCG
|
| Injection, powder, for solution | Subcutaneous |
80 MCG
|
| Powder | — |
100 mcg/1vial
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P17181 | IFNAR1 | Interferon alpha/beta receptor 1 | Homo sapiens | agonist | Link |
| target | P48551 | IFNAR2 | Interferon alpha/beta receptor 2 | Homo sapiens | agonist | Link |
| enzyme | P05177 | CYP1A2 | Cytochrome P450 1A2 | Homo sapiens | inhibitor | Link |
| enzyme | P10635 | CYP2D6 | Cytochrome P450 2D6 | Homo sapiens | inhibitor | Link |
| enzyme | P11712 | CYP2C9 | Cytochrome P450 2C9 | Homo sapiens | inducer | Link |